Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. The Company's pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. The Company's approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System and nanoparticle and hybrid gene delivery technologies as well as in-house cell therapy manufacturing. The Company has formed a global strategic collaboration with Roche to unlock the promise of cell therapies for patients with hematological malignancies. Learn more at www.poseida.com.

Astellas Pharma

Boxer Capital

Longitude Capital

Pentwater Capital Management

Perceptive Advisors

Rapha Capital Management

Malin Corporation

Aisling Capital

Schonfeld Strategic Advisors

Fidelity

Fidelity Management and Research Company

Adage Capital Management

Poseida Therapeutics, Inc.

Regenxbio Inc is a biotechnology company that focuses on the development, commercialization, and licensing of gene therapy treatments.

Regenxbio Inc

TCR2 Therapeutics is a clinical-stage immunotherapy company that develops novel T cell therapies for patients suffering from cancer.

TCR2 Therapeutics

DiaCarta is a molecular diagnostics company that specializes in the development and commercialization of innovative blood-based tests for cancer detection and monitoring.

DiaCarta

Mission Bio is a life sciences company that develops and commercializes single-cell DNA analysis solutions for cancer research and precision medicine applications.

Mission Bio

Quadrants Scientific is a company that provides innovative scientific and laboratory solutions, including products and services for the biotechnology and pharmaceutical industries.

Quadrants Scientific

Poseida Therapeutics is a clinical-stage biopharmaceutical company focused on developing groundbreaking cell and gene therapies for patients with high unmet medical needs. The company's genetic engineering technologies aim to redefine treatment paradigms for life-threatening cancers and genetic diseases.

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

company_structure

crunchbase_trigger

crunchbase_profile

li_profile

translate_crunchbase_fundingrounds

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general	Feb 16, 2024 12:50 AM	af64a3f7
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 16, 2024 12:50 AM	d0e89c3e
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general
news processing advanced	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Feb 16, 2024 12:50 AM	b9500b6a
translate crunchbase fundingrounds	general
peers	general	Feb 16, 2024 12:50 AM	35da72e5
news basic	general	Feb 16, 2024 12:50 AM	953ad404
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
company structure	company_analysis
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

COM:POSEIDA

Poseida Therapeutics, Inc.

Last Close

2.93

08/11 21:00

Market Cap

288.93M

Beta: -

Volume Today

1.24M

Avg: -